Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 7 | 2024 | 716 | 1.090 |
Why?
|
| Pulmonary Valve | 4 | 2024 | 93 | 0.940 |
Why?
|
| Blood Volume | 1 | 2021 | 55 | 0.790 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 210 | 0.720 |
Why?
|
| Hemodynamics | 2 | 2021 | 982 | 0.610 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 794 | 0.430 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 60 | 0.420 |
Why?
|
| Organ Transplantation | 1 | 2023 | 162 | 0.360 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 1836 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 177 | 0.320 |
Why?
|
| Retrospective Studies | 12 | 2024 | 12843 | 0.240 |
Why?
|
| Pulmonary Valve Insufficiency | 2 | 2021 | 42 | 0.230 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 29 | 0.220 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2023 | 17 | 0.220 |
Why?
|
| Pancreatic Cyst | 1 | 2023 | 47 | 0.220 |
Why?
|
| Sentinel Lymph Node | 1 | 2022 | 40 | 0.210 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 83 | 0.200 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 125 | 0.200 |
Why?
|
| Vital Signs | 1 | 2021 | 38 | 0.200 |
Why?
|
| Virtual Reality | 1 | 2021 | 39 | 0.190 |
Why?
|
| Radiation Exposure | 1 | 2021 | 41 | 0.190 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 276 | 0.180 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 123 | 0.170 |
Why?
|
| Heart Rate | 1 | 2021 | 708 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 343 | 0.150 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 450 | 0.150 |
Why?
|
| Cardiac Catheterization | 4 | 2021 | 539 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 310 | 0.150 |
Why?
|
| Melanoma | 1 | 2022 | 664 | 0.140 |
Why?
|
| Pain | 1 | 2021 | 719 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 764 | 0.130 |
Why?
|
| Humans | 17 | 2024 | 117083 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 975 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2021 | 1618 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 698 | 0.120 |
Why?
|
| Reference Values | 1 | 2024 | 751 | 0.110 |
Why?
|
| Adolescent | 3 | 2024 | 18219 | 0.100 |
Why?
|
| Pancreatectomy | 2 | 2024 | 166 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 1771 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2831 | 0.100 |
Why?
|
| Child | 3 | 2024 | 18881 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 2222 | 0.090 |
Why?
|
| Pancreas | 1 | 2023 | 278 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 1207 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2024 | 5051 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2024 | 9263 | 0.080 |
Why?
|
| Echocardiography | 2 | 2021 | 564 | 0.080 |
Why?
|
| Age Factors | 1 | 2024 | 2951 | 0.070 |
Why?
|
| Prevalence | 1 | 2023 | 2300 | 0.070 |
Why?
|
| Male | 6 | 2024 | 56694 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 1355 | 0.060 |
Why?
|
| Colorado | 1 | 2024 | 4124 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 36 | 0.060 |
Why?
|
| Cyst Fluid | 1 | 2023 | 27 | 0.060 |
Why?
|
| Middle Aged | 4 | 2024 | 27183 | 0.060 |
Why?
|
| Multilocus Sequence Typing | 1 | 2022 | 12 | 0.050 |
Why?
|
| Female | 5 | 2024 | 60665 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2023 | 126 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 99 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2023 | 127 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2022 | 146 | 0.050 |
Why?
|
| Sirolimus | 1 | 2023 | 193 | 0.050 |
Why?
|
| Infant | 1 | 2024 | 8133 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 238 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2024 | 9323 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 100 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2021 | 140 | 0.050 |
Why?
|
| Angiography | 1 | 2021 | 179 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1144 | 0.040 |
Why?
|
| Adult | 1 | 2021 | 31009 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1105 | 0.040 |
Why?
|
| Altitude | 1 | 2023 | 412 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 460 | 0.040 |
Why?
|
| Young Adult | 1 | 2024 | 10680 | 0.040 |
Why?
|
| Pain Management | 1 | 2021 | 289 | 0.040 |
Why?
|
| United States | 2 | 2023 | 12385 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 1053 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 1372 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 443 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1374 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 19367 | 0.030 |
Why?
|
| Anxiety | 1 | 2021 | 857 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 4507 | 0.030 |
Why?
|